PHARMACOM JAROS – Tirzapatide -15 MG / VIAL -2 ML VIAL

JAROS

 – Tirzepatide – 15 MG / VIAL – 2 ML VIAL – Pharmacom LABS

• JAROS 15 MG is a tirzepatide-based product designed for weight loss and the treatment of type II diabetes mellitus.
• Tirzepatide is a dual incretin agonist (GIP & GLP-1) that provides superior metabolic control by targeting multiple pathways involved in glucose regulation and appetite control.
• JAROS improves glycemic control by enhancing insulin secretion, reducing glucagon release, and improving insulin sensitivity.
• The compound significantly reduces appetite, increases satiety, lowers caloric intake, and reduces food cravings, leading to marked body-weight reduction.
• Clinical data indicate improvements in lipid profile, reductions in systolic blood pressure, and a decreased risk of cardiovascular disease associated with excess body weight.
• The majority of weight loss observed during tirzepatide use is attributed to adipose tissue reduction, with preservation of lean mass.
• Tirzepatide has a long active half-life, allowing for once-weekly subcutaneous administration.
• JAROS does not affect sex hormone production, making it suitable for both men and women, and no post-cycle therapy (PCT) is required after discontinuation.
• JAROS is supplied as a peptide dry powder and must be reconstituted with water for injection prior to use.

Tirzepatide